Tumour-associated antigens: Considerations for their use in tumour immunotherapy

International Journal of Hematology

Volumn 93, Issue 3, 2011, Pages 263-273

  Linley, Adam J ^a   Ahmad, Murrium ^a   Rees, Robert C ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Immune escape; Immunotherapy; Leukaemia associated antigen; Malignant phenotype; Tumour associated antigen

Indexed keywords

CANCER TESTIS ANTIGEN; LEUKEMIA ANTIGEN; TUMOR ANTIGEN; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL DIFFERENTIATION; CELL LINEAGE; GENE DELETION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA STEM CELL; NONHUMAN; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 79955822206     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0783-1     Document Type: Review

References (151)

1. Hanahan D, Weinberg R. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
2. Pleasance E, Stephens P, O'Meara S, McBride D, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463:184-90.
3. Pleasance E, Cheetham R, Stephens P, McBride D, Humphray S, Greenman C, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463:191-6.
4. Felsher D. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res. 2008;68:3081-6.
5. Weinstein I, Joe A. Oncogene addiction. Cancer Res. 2008;68:3077-80.
6. Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G, et al. Patterns of somatic mutations in human cancer genomes. Nature. 2007;446:153-8. (Pubitemid 46398669)
7. Stratton M, Campbell P, Futreal P. The cancer genome. Nature. 2009;458:719-24.
8. Der C, Krontiris T, Cooper G. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA. 1982;79:3637-40.
9. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-7. (Pubitemid 21917508)
10. Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Engl J Med. 2009;361:123-34.
11. Fong P, Yap T, Boss D, Carden C, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28:2512-9.
12. Sandhu S, Yap T, de Bono J. Poly (ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer. 2010;46:9-20.
13. Dunn G, Bruce A, Ikeda H, Old L, Schreiber R. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-8. (Pubitemid 35363648)
14. Dunn G, Old L, Schreiber R. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-48. (Pubitemid 39094044)
15. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother. 2005;54:187-207.
16. Peoples G, Goedegebuure P, Smith R, Linehan D, Yoshino I, Eberlein T. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA. 1995;92:432-6.
17. Brossart P, Heinrich K, Stuhler G, Behnke L, Reichardt V, Stevanovic S, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999;93:4309-17. (Pubitemid 29279274)
18. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-93. (Pubitemid 30017254)
19. Azuma T, Makita M, Ninomiya K, Fujita S, Harada M, Yasukawa M. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol. 2002;116:601-3. (Pubitemid 34178660)
20. Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukaemia - definition of leukaemia-associated antigens and current clinical protocols targeting these antigens. Haematologica. 2006;91:1653-61. (Pubitemid 46039635)
21. Ramanathan R, Lee K, McKolanis J, Hitbold E, Schraut W, Moser A, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced prostate cancer. Cancer Immunol Immunother. 2005;54:254-64. (Pubitemid 40174243)
22. Bos J. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-9. (Pubitemid 19213607)
23. Downward J. Targeting ras signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22. (Pubitemid 37328883)
24. Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chromic myeloid leukemia. N Engl J Med. 2001;344:1031-7. (Pubitemid 32267972)
25. Pandolfi P. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet. 2001;10:769-75. (Pubitemid 32331587)
26. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370:342-50. (Pubitemid 47094995)
27. Riley C, Mathieu M, Clark R, McArdle S, Rees R. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? Cancer Immunol Immunother. 2009;58:489-99.
28. Brichard V, van Pel A, Wolfel T, Wolfel C, De Plaan E, Lethe B, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178:489-95. (Pubitemid 23218197)
29. Kawakami Y, Eliyahu S, Delgado C, Robbins P, Rivoltini L, Topalian S, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91:3515-9. (Pubitemid 24139460)
30. Kawakami Y, Eliyahu S, Delgado C, Robbins P, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 1994;91:6458-62.
31. Wang R, Robbins P, Kawakami Y, Kang X, Rosenberg S. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med. 1995;181:799-804.
32. Corman J, Sercarz E, Nanda N. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol. 1998;144:166-72. (Pubitemid 28505714)
33. Jaramillo A, Majumder K, Manna P, Fleming T, Doherty G, Dipersio J, et al. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int J Cancer. 2002;102:499-506. (Pubitemid 35316005)
34. Rosenberg S, Restifo N, Yang J, Morgan R, Dudley M. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308. (Pubitemid 351430867)
35. Rosenberg S, Dudley M. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233-40.
36. Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S. Human papillomavirus and human cancer. Lancet. 2007;370:890-907.
37. Lajer C, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS. 2010;118:510-9.
38. Young L, Murray P. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22:5108-21. (Pubitemid 37059592)
39. Thompson M, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10:803-21. (Pubitemid 38198878)
40. Grassman R, Aboud M, Jeang K. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene. 2005;24:5976-85. (Pubitemid 43086115)
41. Boxus M, Willems L. Mechanisms of HTLV-1 persistence and transformation. Br J Cancer. 2009;101:1497-501.
42. Hassan M, Selimovic D, Ghozlan H, Abdel-Kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology. 2009;49:1469-82.
43. Tsai W, Chung R. Viral hepatocarcinogensis. Oncogene. 2010;29:2309-24.
44. +-T-cell response by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol. 2004;78:768-78.
45. Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, et al. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci. 2008;99:1633-42.
46. Hung C, Wu T, Monie A, Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev. 2008;222:43-69. (Pubitemid 351430384)
47. Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematop. 2010;50:9-25.
48. Antinore M, Birrer M, Patel D, Nader L, McChance D. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J. 1996;15:1950-60. (Pubitemid 26119228)
49. Hwang S, Lee D, Kim J, Seo T, Choe J. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J Biol Chem. 2002;277:2923-30. (Pubitemid 34953326)
50. Malanchi I, Accardi R, Diehl F, Smet A, Androphy E, Hoheisel J, et al. Human papillomavirus Type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. J Virol. 2004;78:13769-78. (Pubitemid 39612774)
51. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010;40:1-13.
52. Harper D. Impact of vaccination with Cervarix™ on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol. 2008;110:11-7.
53. Haas G Jr, D'Cruz O, DeBault L. Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. Am J Reprod Immunol Microbiol. 1988;18:47-51. (Pubitemid 19020259)
54. Hubank M, Schatz D. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res. 1994;22:5640-8.
55. Scanlan M, Simpson A, Old L. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4.
56. Simpson A, Caballero O, Jungbluth A, Chen Y, Old L. Cancer/ testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615-25.
57. Linley A, Miles A, Al Fawaz M, Lu C, McArdle S, Rees R, et al. Non-X-linked cancer/testis antigens: identification, expression profile and immunogenicity. Curr Trends Immunol. 2009;10:49-59.
58. Liggins A, Lim S, Sollieux E, Pulford K, Banham A. A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun. 2010; 10.
59. Mathieu M, Knights A, Pawelec G, Riley C, Wernet D, Lemonnier F, et al. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunol Immunother. 2007;56:1885-95.
60. Miles A, Rogers A, Li G, Seth R, Powe D, McArdle S, et al. Identification of a novel prostate cancer-associated tumor antigen. Prostate. 2007;67:274-87.
61. Mathieu M, Linley A, Reeder S, Badoual C, Tartour E, Rees R, et al. HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. Cancer Immun. 2010;10.
62. Greiner J, Bullinger L, Guinn B, Döhner H, Schmitt M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukaemia cells. Clin Cancer Res. 2008;14:161-6.
63. Kufe D. Oncogenic function of the MUC1 receptor subunit gene regulation. Oncogene. 2010;29:5663-6.
64. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa K, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukaemia. Blood. 1994;84:3071-9. (Pubitemid 24328100)
65. Tamaki H, Ogwawa H, Ohyashiki K, Oyashiki J, Iwama H, Inoue K, et al. The Wilm's tumour gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia. 1999;13:393-9. (Pubitemid 29108078)
66. Pellat-Deceunynck C, Mellerin M, Labarrieré N, Jego G, Moreau- Aubry A, Harousseau J, et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol. 2000;30:803-9. (Pubitemid 30216252)
67. Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R. PRAME mRNA levels in cases with acute leukaemia: clinical importance and future prospects. Am J Hematol. 2005;79:257-61. (Pubitemid 41098836)
68. Proto-Siqueira R, Figueiredo-Pontes L, Panepucci R, Garcia A, Rizzatti E, Nascimento F, et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukaemia and mantle cell lymphoma. Leuk Res. 2006;30:1333-9. (Pubitemid 44307321)
69. Arons E, Suntum T, Marguiles I, Yuan C, Stetler-Stevenson M, Kreitman R. PRAME expression in hairy cell leukaemia. Leuk Res. 2008;32:1400-6.
70. Dao T, Scheinberg D. Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol. 2008;21:391-404.
71. Sugiyama H. WT1 (Wilms' Tumor Gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40:377-87.
72. Epping M, Wang L, Edel M, Carlée L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122:835-47. (Pubitemid 41345202)
73. Oehler V, Guthrie K, Cummings C, Sabo K, Wood B, Gooley T, et al. The preferentially expressed antigen of melanoma (PRAME) inhibits myeloid differentiation in normal hemapoietic and leukemic progenitor cells. Blood. 2009;114:3299-308.
74. Tsuboi A, Oka Y, Ogawa H, Elisseeva O, Tamaki H, Oji Y, et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor. Leuk Res. 1999;23:499-505. (Pubitemid 29223079)
75. Loeb D, Summers J, Burwell E, Korz D, Friedman A, Sukumar S. An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation. Leukemia. 2003;17:965-71. (Pubitemid 36626325)
76. Gu W, Chen Z, Hu S, Shen H, Qiu G, Cao X. Changes in expression of WT1 isoforms during induced differentiation of the NB4 cell line. Haematologica. 2005;90:403-5. (Pubitemid 40388992)
77. Simpson L, Burwell E, Thompson K, Shahnaz S, Chen A, Loeb D. The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood. 2006;107:4695-702. (Pubitemid 43882617)
78. Vincent S, Chen R, Sayles L, Lin C, Walker R, Gillespie A, et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest. 2010;120:3940-52.
79. Cesaro E, Montano G, Rosati A, Crescitelli R, Izzo P, Turco M, et al. WT1 protein is a transcriptional activator of the antiapoptotic bag3 gene. Leukemia. 2010;24:1204-6.
80. Tchirkov A, Chaleteix C, Magnac C, Vasconcelos Y, Davi F, Michel A, et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol. 2004;15:1476-80. (Pubitemid 39409736)
81. Huh H, Huh J, Yoo E, Seong C, Lee M, Hong K, et al. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol. 2005;79:267-73. (Pubitemid 41098838)
82. Kuhlmann A, Villaudy J, Gazzolo L, Castellazzi M, Mesnard J, Dodon M. HTLV-1 HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT). Retrovirology. 2007;4.
83. Bellon M, Nicot C. Central role of PI3 K in transcriptional activation of hTERT in HTLV-I infected cells. Blood. 2008;112:2946-55.
84. Hara T, Matsumura-Arioka Y, Ohtani K, Nakamura M. Role of human T-cell leukemia virus type I Tax in expression of the human telomerase reverse transcriptase (hTERT) gene in human T-cells. Cancer Sci. 2008;99:1155-63. (Pubitemid 351676627)
85. Briatore F, Barrera G, Pizzimenti S, Toaldo C, Della Casa C, et al. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biol Ther. 2009;8:883-9.
86. Yamaguchi H, Calado R, Ly H, Kajigaya S, Baerlocher G, Chanock S, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anaemia. N Engl J Med. 2005;352:1413-24. (Pubitemid 40471449)
87. Vaziri H, Schächter F, Uchida I, Wei L, Zhu W, Effros R, et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet. 1993;52:661-7. (Pubitemid 23310132)
88. Hastie N, Dempster M, Dunlop M, Thompson A, Green D, Allshire R. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990;346:866-8.
89. Bodnar A, Ouelette M, Frolkis M, Holt S, Chiu C, Morin G, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349-52. (Pubitemid 28063364)
90. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol. 1998;8:279-82. (Pubitemid 28111458)
91. Vonderheide R. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie. 2008;90:173-80. (Pubitemid 350216207)
92. Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res. 2000;60:3848-55. (Pubitemid 32204577)
93. Adams S, Sahota S, Mijovic A, Czepulkowski B, Padua R, Mufti G, et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia. 2002;16:2238-42. (Pubitemid 35331839)
94. Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M. Cancer/testis genes in multiple myeloma: expression patterns and prognosis values determined by microarray analysis. J Immunol. 2007;178:3307-15. (Pubitemid 46333216)
95. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo J, Navarro G, San Jose-Eneriz E, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukaemia. Haematologica. 2007;92:153-62.
96. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo J, Navarro G, San Jose-Eneriz E, et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res. 2007;31:1521-8. (Pubitemid 350010966)
97. Ortmann C, Eisele L, Nückel H, Klein-Hitpass L, Führer A, Dührsen U, et al. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol. 2008;87:809-18.
98. Leutkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels B, et al. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res. 2010;34:1647-55.
99. Coppes M, Campbell C, Williams B. The role of WT1 in Wilms tumorigenesis. FASEB J. 1993;7:886-95. (Pubitemid 23225545)
100. Bonnet D, Dick J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-7. (Pubitemid 27298715)
101. Bonnet D. Normal and leukaemic stem cells. Br J Haematol. 2005;130:469-79. (Pubitemid 43899749)
102. Abdel-Wahab O, Levine R. Metabolism and the leukemic stem cell. J Exp Med. 2010;207:677-80.
103. Testa U. Leukemia stem cells. Ann Hematol. 2010;90:245-71.
104. Allies L, Weissman I. Cancer stem cells in solid tumours. Curr Opin Biotechnol. 2007;18:460-6. (Pubitemid 350116595)
105. Bjerkvig R, Johansson M, Miletic H, Niclou S. Cancer stem cells and angiogenesis. Semin Cancer Biol. 2009;19:279-84.
106. Al-Hajj M, Wicha M, Benito-Henandez A, Morrison S, Clarke M. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-8. (Pubitemid 36418143)
107. Ponti D, Zaffaroni N, Capelli C, Diadone M. Breast cancer stem cells: an overview. Eur J Cancer. 2006;42:1219-24. (Pubitemid 43795092)
108. Signoretti S, Loda M. Prostate stem cells: from development to cancer. Semin Cancer Biol. 2007;17:219-24. (Pubitemid 46413076)
109. Prince M, Sivanandan R, Kaczorokowski A, Wolf G, Kaplan M, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104:973-8. (Pubitemid 46154721)
110. Huang E, Heidt D, Li C, Simeone D. Cancer stem cells: a new paradigm for understanding tumour progression and therapeutic resistance. Surgery. 2007;141:415-9. (Pubitemid 46441320)
111. Passegué E, Jamieson C, Ailles L, Weissman I. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA. 2003;100:11842-9.
112. Ribas A, Butterfield L, Glaspy J, Economou J. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;21:2415-32. (Pubitemid 46621880)
113. Rosenberg S, Yang J, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-15. (Pubitemid 39273730)
114. Nencioni A, Brossart P. Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells. 2004;22:501-13. (Pubitemid 39014566)
115. Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A. Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev. 2008;60:173-83. (Pubitemid 350236398)
116. Melief C. Cancer immunotherapy by dendritic cells. Immunity. 2008;29:372-83.
117. Jaini R, Kesaraju P, Johnson J, Altuntas C, Jane-wit D, Tuohy V. An auto-immune-mediated strategy for prophylactic breast cancer vaccination. Nat Med. 2010;16:799-803.
118. Rosenberg S, Yannelli J, Yang J, Topalian S, Schwartzentruber D, Weber J, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159-66. (Pubitemid 24249302)
119. Dudley M, Yang J, Sherry R, Hughes M, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-9.
120. Panelli M, Bettinotti M, Lally K, Ohnmacht G, Li Y, Robbins P, et al. A tumour-infiltrating lymphocyte from a melanoma metastases with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J Immunol. 2000;164:4382-92. (Pubitemid 30215102)
121. Seiter S, Monsurro V, Nielsen M, Wang E, Provensano M, Wunderlich J, et al. Frequency of MART-1/Melan-A and gp100/ pmel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother. 2002;25:252-63. (Pubitemid 34533315)
122. Weynants P, Thonnard J, Marchand M, Delos M, Boon T, Coulie P. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. Am J Respir Crit Care Med. 1999;159:55-62. (Pubitemid 29036503)
123. Heidecker L, Brasseur F, Probst-Kepper M, Gueguen M, Boon T, van den Eynde B. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J Immunol. 2000;164:6041-5. (Pubitemid 30389854)
124. Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali M, et al. Downregualtion of major histocompatibility complex antigens in invading glioma cells: stealth invasion into the brain. Lab Invest. 2005;85:328-41. (Pubitemid 40333150)
125. Chang C, Ogino T, Mullins D, Oliver J, Yamshchikov G, Bandoh N, et al. Defective human leukocyte antigen class-I-associated antigen presentation caused by a novel β2- microglobulin loss-of-function in melanoma cells. J Biol Chem. 2006;281:18763-73. (Pubitemid 44035537)
126. Ferris R, Whiteside T, Ferrone S. Immune escape associated with functional defects in antigen processing machinery in head and neck cancer. Clin Cancer Res. 2006;12:3890-5. (Pubitemid 44078071)
127. Setiadi A, David M, Seipp R, Hartikainen J, Gopaul R, Jefferies W. Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol Cell Biol. 2007;27:7886-94. (Pubitemid 350086422)
128. Cabrera T, Lopez-Nevot M, Gaforio J, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumour tissues. Cancer Immunol Immunother. 2003;52:1-9. (Pubitemid 36177220)
129. McKee M, Roszkowski J, Nishimura M. T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med. 2005;3.
130. Macián F, Im S, Garcia-Cózar F, Rao A. T-cell anergy. Curr Opin Immunol. 2004;16:209-16. (Pubitemid 38328721)
131. Oosterwegel M, Greenwald R, Mandelbrot D, Lorsbach R, Sharpe A. CTLA-4 and T-cell activation. Curr Opin Immunol. 1999;11:294-300.
132. Li Z, Chen L, Qin Z. Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol. 2009;6:415-22.
133. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL- 17. J Immunol. 2009;183:4169-75.
134. Nagaraj N, Datta P. Targeting the transforming growth factor-β signaling pathway in human cancer. Expert Opin Investig Drugs. 2010;19:77-91.
135. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170-81.
136. Nagata S, Goldstein P. The Fas death factor. Science. 1995;267:1449-56.
137. Minas V, Rolaki A, Kalantaridou SN, Sidiropoulos J, Mitrou S, Petsas G, et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through Fasl regulation. Br J Cancer. 2007;97:637-45. (Pubitemid 47339889)
138. O'Connell J, Bennett M, O'Sullivan G, Collins J, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today. 1999;20:46-52. (Pubitemid 29136550)
139. Bennett M, O'Connell J, O'Sullivan G, Brady C, Roche D, Collins J, Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumour-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol. 1998;160:5669-75. (Pubitemid 28267863)
140. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French L, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996;274:1363-6. (Pubitemid 26391458)
141. Chappell D, Zaks T, Rosenberg S, Restifo N. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 1999;59:59-62. (Pubitemid 29062956)
142. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation- induced cell death: the controversial role of Fas and Fasl-igand in immune privilege and tumour counterattack. Immunol Cell Biol. 2002;80:131-7. (Pubitemid 34298085)
143. Groux H. An overview of regulatory T cells. Microbes Infect. 2001;3:883-9. (Pubitemid 32835301)
144. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7:875-88. (Pubitemid 350006238)
145. Sakaguchi S, Wing K, Yamaguchi T. Dynamics of peripheral tolerance and immune regulation by Treg. Eur J Immunol. 2009;39:2331-6.
146. + regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490-500.
147. Grossman W, Verbsky J, Barchet W, Colonna M, Atkinson J, Ley T. Human T regulatory cells can use the perforin pathway to cause autologous T cell death. Immunity. 2004;21:589-601. (Pubitemid 39370513)
148. Roncarolo M, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings M. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:25-50.
149. Strauss L, Bergmann C, Whiteside T. Human circulating CD4+CD25 high Foxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol. 2009;182:1469-80.
150. + regulatory T cell mediated immunosuppression. Cytokine Growth Factor Rev. 2003;14:85-9.
151. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-86.